Company Reports

Tilray's fiscal third-quarter 2026 net revenue increased 11% to USD 207 million. The 19% revenue growth in the cannabis segment and 35% growth in the distribution segment offset a 24% decline in the beverage segment. Adjusted EBITDA margin expanded about 32 basis points to 5.2%.

We will discontinue analyst coverage of Tilray Brands on or about April 20.

Tilray cultivates and sells cannabis in Canada and exports into the global medical market. It also sells Cannabidiol, or CBD, and alcohol. The company is the result of legacy Aphria acquiring legacy Tilray in a reverse merger and taking the target name in 2021.

Tilray's fiscal second-quarter 2026 net revenue increased 3% to USD 218 million. The 3% revenue growth in the cannabis segment and 26% growth in the distribution segment offset a 20% decline in beverage. Adjusted EBITDA margin declined about 20 basis points to 4.1%.

On Dec. 18, President Trump signed an executive order directing federal agencies to lower cannabis' status to Schedule III from Schedule I. This follows a Washington Post report last week that signalled the move would be coming soon.

On Dec. 11, the Washington Post reported that President Donald Trump would issue an executive order to reclassify cannabis to Schedule III from Schedule I as soon as next week. Federal agencies would then begin the process, though it could take six months to a year for the rule to go into effect.

On Dec. 2, Tilray shares began trading to reflect the previously announced 1-for-10 reverse stock split. Outstanding common shares should fall to 116 million from 1.6 billion.

Tilray cultivates and sells cannabis in Canada and exports into the global medical market. It also sells Cannabidiol, or CBD, and alcohol. The company is the result of legacy Aphria acquiring legacy Tilray in a reverse merger and taking the target name in 2021.

On Nov. 10, the US Senate passed a funding bill that included a provision banning the sale of hemp-derived products that include more than 0.4 milligrams of THC. This would potentially halt the sale of gray-market delta-8 and delta-9 as well as popular THC beverages produced by craft brewers.

Tilray cultivates and sells cannabis in Canada and exports into the global medical market. It also sells CBD and alcohol. The company is the result of legacy Aphria acquiring legacy Tilray in a reverse merger and taking the target name in 2021.

Tilray reported that fiscal first-quarter 2026 net revenue increased 5% to USD 200 million. Cannabis revenue grew 5%, while sales of alcoholic beverages declined less than 1%. Adjusted EBITDA margin increased about 20 basis points to 4.9%.

On Sept. 29, shares of Curaleaf were up more than 30%, Green Thumb up nearly 20%, and Tilray up more than 50%. The rally followed President Donald Trump's social media repost of a video touting the benefits of CBD for the elderly.

Tilray cultivates and sells cannabis in Canada and exports into the global medical market. It also sells CBD and alcohol. The company is the result of legacy Aphria acquiring legacy Tilray in a reverse merger and taking the target name in 2021.

Tilray reported fiscal fourth-quarter 2025 results, with net revenue declining 2% year over year to $224.5 million. Cannabis revenue declined by 6%, while alcoholic beverages plunged 14%. Adjusted EBITDA margins declined about 50 basis points to 12.3%.

Shares of Curaleaf were up 22%, Green Thumb up 9%, and Tilray down 6% on July 10. The optimism behind this rally seems to stem from political influencers pushing a viral campaign for rescheduling cannabis to a lower classification than its current Schedule I classification in the US.

Tilray cultivates and sells cannabis in Canada and exports into the global medical market. It also sells CBD and alcohol. The company is the result of legacy Aphria acquiring legacy Tilray in a reverse merger and taking the target name in 2021.

Tilray reported fiscal third-quarter 2025 earnings, with net revenue declining 1% year over year to $186 million. However, excluding the effect of currency, net revenue would have grown 2%. Adjusted EBITDA margins declined about 60 basis points to 4.8%.

Tilray reported second-fiscal-quarter 2025 earnings, with net revenue growing 9% year over year to $211 million. However, most of that growth came from acquisition in the alcoholic beverages segment, while the cannabis segment's net revenue declined 2% to $66 million.

Tilray cultivates and sells cannabis in Canada and exports into the global medical market. It also sells CBD and alcohol. The company is the result of legacy Aphria acquiring legacy Tilray in a reverse merger and taking the target name in 2021.

Tilray cultivates and sells cannabis in Canada and exports into the global medical market. It also sells CBD and alcohol. The company is the result of legacy Aphria acquiring legacy Tilray in a reverse merger and taking the target name in 2021.